Guggenheim Upgrades Editas Medicine Stock to Buy
On Wednesday, Guggenheim upgraded its rating for Editas Medicine (NASDAQ: EDIT) from Neutral to Buy. The upgrade is based on the company's development of a novel gene editing therapy called EDIT-401, which targets hyperlipidemia—a condition characterized by severely high blood cholesterol levels. Analyst Debjit Chattopadhyay highlighted that this approach could represent a significant advancement in treating patients with genetic lipid disorders. The upgrade comes as Editas prepares to advance its clinical development plans for the therapy, potentially positioning it as an innovative solution within the gene editing space and attracting investor interest.
